WESTON (dpa-AFX) - Biogen Idec (BIIB) said Tuesday that it has completed its purchase of Irish drugmaker Elan Corp.'s (ELN, ELA.L) interest in multiple sclerosis drug Tysabri and has gained full strategic, commercial and decision-making rights to Tysabri.
On February 6, Biogen Idec announced that it has agreed to buy Irish Elan's interest in Tysabri for $3.25 billion in upfront payment.
As a result of the acquisition from Elan, Tysabri will be marketed and distributed solely by Biogen Idec.
Biogen Idec said it will provide further details and updated financial guidance during its upcoming first quarter earnings announcement.
TYSABRI is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, generally for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy due to the risk of progressive multifocal leukoencephalopathy.
In the European Union, Tysabri is approved for highly active relapsing-remitting MS in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe relapsing-remitting MS.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
